Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 41.56% is in line with its 5-year average of 40.47%, around the middle of its 5-year range (24.84%–51.94%).
1.41% above its 12-month average of 40.98%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 42.51%.
NET PROFIT MARGIN
41.56%
NET PROFIT MARGIN AVG TTM
40.98%
NET PROFIT MARGIN AVG 3Y
41.12%
NET PROFIT MARGIN AVG 5Y
40.47%
NET PROFIT MARGIN AVG 10Y
37.46%
NET PROFIT MARGIN AVG 15Y
36.49%
NET PROFIT MARGIN AVG 20Y
28.62%
CURRENT VS TTM AVG
+1.41%
CURRENT VS 3Y AVG
+1.08%
CURRENT VS 5Y AVG
+2.68%
CURRENT VS 10Y AVG
+10.94%
CURRENT VS 15Y AVG
+13.90%
CURRENT VS 20Y AVG
+45.21%
SECTOR MEDIAN · HEALTHCARE
9.21%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+351.49%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$21.10B
Net Profit Margin
41.56%
TTM Avg
40.98%
3Y Avg
41.12%
5Y Avg
40.47%
Market Cap
$19.23B
Net Profit Margin
-2.79%
TTM Avg
-14.44%
3Y Avg
-3.94%
5Y Avg
-4.74%
Market Cap
$18.09B
Net Profit Margin
9.48%
TTM Avg
10.17%
3Y Avg
9.38%
5Y Avg
6.86%
Market Cap
$24.30B
Net Profit Margin
-62.98%
TTM Avg
-31.89%
3Y Avg
3.77%
5Y Avg
12.08%
Market Cap
$24.37B
Net Profit Margin
16.98%
TTM Avg
16.55%
3Y Avg
18.38%
5Y Avg
18.84%
Market Cap
$24.62B
Net Profit Margin
27.71%
TTM Avg
12.90%
3Y Avg
13.00%
5Y Avg
12.11%
Market Cap
$25.55B
Net Profit Margin
6.99%
TTM Avg
6.01%
3Y Avg
6.56%
5Y Avg
9.24%
Market Cap
$16.40B
Net Profit Margin
17.67%
TTM Avg
18.50%
3Y Avg
17.20%
5Y Avg
16.74%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $21.10B | 41.56% | 40.98% | 41.12% | 40.47% |
| STERIS plc (STE)vs › | $20.54B | 13.33% | 12.25% | 8.55% | 8.79% |
| Viatris Inc. (VTRS)vs › | $19.23B | -2.79% | -14.44% | -3.94% | -4.74% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.09B | 9.48% | 10.17% | 9.38% | 6.86% |
| BioNTech SE (BNTX)vs › | $24.30B | -62.98% | -31.89% | 3.77% | 12.08% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.37B | 16.98% | 16.55% | 18.38% | 18.84% |
| Incyte Corporation (INCY)vs › | $24.62B | 27.71% | 12.90% | 13.00% | 12.11% |
| Labcorp Holdings Inc. (LH)vs › | $25.55B | 6.99% | 6.01% | 6.56% | 9.24% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.40B | 17.67% | 18.50% | 17.20% | 16.74% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.94B | 9.19% | 8.91% | 9.15% | 11.71% |
Operating Margin
44.5%
Net Profit Margin
41.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 42.51% |
| 2026-03-31 | 35.18% |
| 2025-12-31 | 46.10% |
| 2025-09-30 | 42.36% |
| 2025-06-30 | 38.76% |
| 2025-03-31 | 40.56% |
| 2024-12-31 | 40.94% |
| 2024-09-30 | 41.27% |
| 2024-06-30 | 38.90% |
| 2024-03-31 | 45.24% |
| 2023-12-31 | 35.32% |
| 2023-09-30 | 43.91% |
| 2023-06-30 | 43.45% |
| 2023-03-31 | 47.52% |
| 2022-12-31 | 26.88% |
| 2022-09-30 | 46.38% |
| 2022-06-30 | 24.84% |
| 2022-03-31 | 51.94% |
| 2021-12-31 | 27.02% |
| 2021-09-30 | 36.59% |
| 2021-06-30 | 38.66% |
| 2021-03-31 | 7.47% |
| 2020-12-31 | 25.67% |
| 2020-09-30 | 45.04% |
| 2020-06-30 | 29.59% |
| 2020-03-31 | 38.65% |
| 2019-12-31 | 16.91% |
| 2019-09-30 | 32.98% |
| 2019-06-30 | 54.90% |
| 2019-03-31 | -136.40% |
| 2018-12-31 | 17.12% |
| 2018-09-30 | 25.81% |
| 2018-06-30 | 38.90% |
| 2018-03-31 | 62.82% |
| 2017-12-31 | 4.09% |
| 2017-09-30 | 62.02% |
| 2017-06-30 | -12.60% |
| 2017-03-31 | 48.21% |
| 2016-12-31 | 26.97% |
| 2016-09-30 | 39.64% |
| 2016-06-30 | 49.95% |
| 2016-03-31 | 63.82% |
| 2015-12-31 | 25.85% |
| 2015-09-30 | 120.25% |
| 2015-06-30 | 28.58% |
| 2015-03-31 | -5.08% |
| 2014-12-31 | 33.47% |
| 2014-09-30 | -7.65% |
| 2014-06-30 | 34.65% |
| 2014-03-31 | 47.52% |
| 2013-12-31 | -10.49% |
| 2013-09-30 | 20.74% |
| 2013-06-30 | 28.46% |
| 2013-03-31 | 25.42% |
| 2012-12-31 | 34.15% |
| 2012-09-30 | 32.21% |
| 2012-06-30 | 32.06% |
| 2012-03-31 | 34.65% |
| 2011-12-31 | 22.13% |
| 2011-09-30 | 41.83% |
| 2011-06-30 | 40.21% |
| 2011-03-31 | 9.90% |
| 2010-12-31 | 5.73% |
| 2010-09-30 | 23.24% |
| 2010-06-30 | 27.43% |
| 2010-03-31 | 14.69% |
| 2009-12-31 | -3.06% |
| 2009-09-30 | 12.28% |
| 2009-06-30 | -2.79% |
| 2009-03-31 | 16.55% |
| 2008-12-31 | -106.96% |
| 2008-09-30 | 16.82% |
| 2008-06-30 | 20.90% |
| 2008-03-31 | 18.38% |
| 2007-12-31 | 3.32% |
| 2007-09-30 | 25.15% |
| 2007-06-30 | 11.20% |
| 2007-03-31 | -6.92% |
| 2006-12-31 | 121.13% |
| 2006-09-30 | 20.99% |
| 2006-06-30 | 19.07% |
| 2006-03-31 | 6.96% |
| 2005-12-31 | 99.22% |
| 2005-09-30 | 47.75% |
| 2005-06-30 | 40.53% |
| 2005-03-31 | 33.01% |
| 2004-12-31 | 31.88% |
| 2004-09-30 | 31.34% |
| 2004-06-30 | 22.62% |
| 2004-03-31 | -13.50% |
| 2003-12-31 | -23.69% |
| 2003-09-30 | -8.92% |
| 2003-06-30 | -17.06% |
| 2003-03-31 | -28.16% |
| 2002-12-31 | -21.67% |
| 2002-09-30 | -237.68% |
